financetom
Market
financetom
/
Market
/
HDFC Bank shares hit 52-week high after CLSA raises target price
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HDFC Bank shares hit 52-week high after CLSA raises target price
Nov 24, 2020 1:10 AM

The share price of HDFC Bank gained over 1 percent to hit a fresh 52-week high of Rs 1,423.35 apiece in the early trade on Tuesday after the global brokerage CLSA maintained its positive view on the stock and raised the target price.

Share Market Live

NSE

CLSA maintained a 'Buy' call on the stock and raised the target price to Rs 1,700 per share from Rs 1,525 earlier. HDFC Bank remains one of CLSA’s top picks.

The brokerage is of the view that the macro environment has improved materially after lockdown, and that coupled with better use of data, analytics and bureau to underwrite is leading to lower retail stress versus past cycles.

“The bank’s CEO transition has been smooth and the bank continues to work on its five-pillar strategy to drive growth targeting newer geographies/ecosystems and the bank is redefining systems/processes, and hence in the medium term Opex efficiency still has room to improve,” CLSA said in a note.

The stock price of HDFC Bank has rallied 92 percent since its 52-week low of Rs 738.90 apiece hit on March 24, 2020. At 9:55 am, the shares of HDFC Bank were trading 1.76 percent higher at Rs 1,419.40 apiece on the BSE as against a 0.70 percent gain in the benchmark Sensex.

Catch all the latest updates from the stock market here.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Sep 22, 2024
Truist Securities has downgraded Incyte Corporation ( INCY ) , noting Jakafi’s (ruxolitinib) patent loss approaching in 2028. Jakafi is Incyte’s top-selling drug. It is indicated for polycythemia vera in adults, intermediate or high-risk myelofibrosis in adults, and steroid-refractory acute graft versus host disease in adult and pediatric patients. In second quarter 2024, the drug generated sales of $705.9 million, +3%...
Sector Update: Consumer Stocks Edge Up in Afternoon Trading
Sector Update: Consumer Stocks Edge Up in Afternoon Trading
Sep 22, 2024
01:43 PM EDT, 09/18/2024 (MT Newswires) -- Consumer stocks rose Wednesday afternoon with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.1% and the Consumer Discretionary Select Sector SPDR Fund (XLY) increasing 0.2%. In corporate news, General Mills' ( GIS ) fiscal Q3 results declined less than market expectations, while the Cheerios maker reiterated its full-year outlook. The shares...
Top Midday Decliners
Top Midday Decliners
Sep 22, 2024
01:54 PM EDT, 09/18/2024 (MT Newswires) -- Cibus ( CBUS ) said Wednesday it priced an underwritten public offering of 3 million shares of its class A common stock at $4 apiece, targeting gross proceeds of about $12 million. Shares slumped 28% amid intraday trading volume at over 1.6 million compared with a daily average of about 177,000. Mullen Automotive...
US Equity Indexes Decline as Investors Await Fed's Policy Move, Guidance on Easing Path
US Equity Indexes Decline as Investors Await Fed's Policy Move, Guidance on Easing Path
Sep 22, 2024
12:15 PM EDT, 09/18/2024 (MT Newswires) -- US equity indexes fell in choppy midday trading Wednesday ahead of the Federal Reserve's policy announcement later in the afternoon. The S&P 500 index fell 0.2% to 5,624.3, with the Nasdaq Composite down 0.3% to 17,574.1 and the Dow Jones Industrial Average 0.1% lower at 41,551.5. Except for gains in consumer staples, energy,...
Copyright 2023-2025 - www.financetom.com All Rights Reserved